Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
Open Access
- 13 March 2019
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 6 (2) , 217-230
Abstract
Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) with different mechanisms of action may vary, based on patients’ serostatus. The aim of this study is to compare the effectiveness of abatacept versus tumor necrosis factor inhibitors (TNFis) in patients with RA who were anti-cyclic citrullinated peptide antibody positive (anti-CCP+).Keywords
Funding Information
- Corrona, LLC
- Bristol-Myers Squibb
This publication has 29 references indexed in Scilit:
- Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2015
- Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesAnnals of the Rheumatic Diseases, 2011
- Development of the anti–citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritisArthritis & Rheumatism, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis CohortThe American Journal of Medicine, 2008
- Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvementAnnals of the Rheumatic Diseases, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donorsArthritis & Rheumatism, 2004
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000